Skip to main content
OpenTrials
Completed

NCT Number: NCT03646851

Aspergillus and Chronic Obstructive Pulmonary Disease Evolution

This is a prospective multicenter cohort study which includes all consecutive COPD patients who come for a visit in one the participating pneumologist. They will have to do a sputum and to complete some questionnaries. Questionnaries will be redone by phone after 1 and 3 months and during the visit after 6 months. We will correlate aspergillus presence in sputum with quality of life (QoL), and COPD symptoms evaluated by questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CH Abbeville, Abbeville, France

Loading trial locations.

About this study

Aspergillosis disease is a growing problem. These diseases are not yet uncommon in chronic obstructive pulmonary disease patients. (COPD).

Aspergillosis disease are very difficult to be diagnosed or treated. Isolation of aspergillus in sputum of patients is not always responsible of a real disease. Need of treatment is discussed. That is why, we will conduct a prospective cohort study to evaluate aspergillus rate in respiratory samples of COPD patients (GOLD stage III or IV)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COPD patients GOLD stage III and IV

Exclusion criteria

  • Cystic fibrosis
  • Pulmonary fibrosis
  • hematological malignancy
  • known aspergilloma
  • allergic bronchopulmonary aspergillosis

Treatment and study plan

Questionnaries

Diagnostic Test

patients will have to do a sputum and to complete some questionnaries

Primary outcomes

  1. presence of aspergillus in sputum or respiratory samples

    Time frame: one year before inclusion

    sputum examination

Secondary outcomes

  1. Dyspnea with MMRC score

    Time frame: day of inclusion

    Pulmonary function testing

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Official study title

Impact of Aspergillus on Chronic Obstructive Pulmonary Disease Evolution

Acronym: AspergBPCO

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 24, 2018
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.